Measuring cognition and function in the preclinical stage of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“The battery enables operationalization of the National Institute on Aging/Alzheimer’s Association core clinical criteria for MCI due to AD [30] by requiring, fulfillment of the clinical criteria across two consecutive examinations at least 6 months apart, consisting of decline in the Clinical Dementia Rating scale sco…”
BackgroundMethodSelf-citationSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationWinblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 2×
“On the one hand, population-based studies have detected subtle cognitive changes in verbal fluency, learning, and recall among individuals in the preclinical stage, and prospective LCSs indicate that a decline in global cognition can be detected in people at risk for AD [9,27].”
BackgroundThe adaptive brain: aging and neurocognitive scaffolding
Park, D. C., & Reuter-Lorenz, P. (2009) · Annual Review of Psychology · doi:10.1146/annurev.psych.59.103006.093656 · Cited by 2,790 · cited 2×
“, the engagement of additional neural circuits, neurogenesis, and other active processes, resulting in some protection from decline in cognitive function [2]).”
BackgroundSelf-citationCognition assessment using the NIH Toolbox
Weintraub, S., Dikmen, S. S., Heaton, R. K., Tulsky, D. S., Zelazo, P. D., Bauer, P. J., Carlozzi, N. E., Slotkin, J., Blitz, D., Wallner-Allen, K., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182872ded · Cited by 1,287 · cited 3×
“For example, markers of AD neuropathology were associated with a decline in episodic memory, semantic memory, and working memory [16].”
BackgroundMethodThe Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860
Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782 · cited 1×
“Amyloid deposition is associated also with the apolipoprotein E (APOE) ε4 genotype [5] and with greater decline in cognitive function over time [6].”
BackgroundProdromal Alzheimer's disease: successive emergence of the clinical symptoms
Amieva, H., Le Goff, M., Millet, X., Orgogozo, J. M., Pérès, K., Barberger‐Gateau, P., Jacqmin‐Gadda, H., & Dartigues, J. F. (2008) · Annals of Neurology · doi:10.1002/ana.21509 · Cited by 737
The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials
Sperling, R., Mormino, E., & Johnson, K. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.038 · Cited by 725 · cited 1×
“Amyloid deposition is associated also with the apolipoprotein E (APOE) ε4 genotype [5] and with greater decline in cognitive function over time [6].”
Background
Cited by
Depression, Anxiety, and Apathy in Mild Cognitive Impairment: Current Perspectives
Ma, L. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00009 · Cited by 323
The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease
Rafii, M. S., Sperling, R. A., Donohue, M. C., Zhou, J., Roberts, C., Irizarry, M. C., Dhadda, S., Sethuraman, G., Kramer, L. D., Swanson, C. J., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12748 · Cited by 291
Current advances in digital cognitive assessment for preclinical Alzheimer's disease
Öhman, F., Hassenstab, J., Berron, D., Schöll, M., & Papp, K. V. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12217 · Cited by 214
“Spoken language analysis and automated language processing New technical developments have provided further insight into language deficits in preclinical AD, and several newly developed analysis FIGURE 3 A, Sea Hero Quest Wayfinding and Path integration.”
BackgroundInfluentialAssunção, S. S., Sperling, R. A., Ritchie, C., Kerwin, D. R., Aisen, P. S., Lansdall, C., Atri, A., & Cummings, J. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00984-y · Cited by 71
BHA-CS: A novel cognitive composite for Alzheimer's disease and related disorders
Tsoy, E., Erlhoff, S. J., Goode, C. A., Dorsman, K. A., Kanjanapong, S., Lindbergh, C. A., La Joie, R., Strom, A., Rabinovici, G. D., Lanata, S. C., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12042 · Cited by 38
Metadata
- Authors
- Weintraub, S., Carrillo, M. C., Farias, S. T., Goldberg, T. E., Hendrix, J. A., Jaeger, J., Knopman, D. S., Langbaum, J. B., Park, D. C., Ropacki, M. T., Sikkes, S. A. M., Welsh‐Bohmer, K. A., Bain, L. J., Brashear, R., Budur, K., Graf, A., Martenyi, F., Storck, M. S., & Randolph, C.
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 4
- Issue
- 1
- Pages
- 64-75
- ISSN
- 2352-8737 (ISSN-L)
- OpenAlex
- W2790394929
- Cited by
- 120
- References
- 27
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Measuring cognition and function in the preclinical stage of Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.trci.2018.01.003
- The paper
- Weintraub, S., Carrillo, M. C., Farias, S. T., Goldberg, T. E., Hendrix, J. A., Jaeger, J., Knopman, D. S., Langbaum, J. B., Park, D. C., Ropacki, M. T., Sikkes, S. A. M., Welsh‐Bohmer, K. A., Bain, L. J., Brashear, R., Budur, K., Graf, A., Martenyi, F., Storck, M. S., & Randolph, C. (2018). Measuring cognition and function in the preclinical stage of Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions. https://doi.org/10.1016/j.trci.2018.01.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.